pCMV-Neo-Bam p53 R273H Citations (21)
Originally described in: Suppression of human colorectal carcinoma cell growth by wild-type p53.Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B Science. 1990 Aug 24. 249(4971):912-5. PubMed Journal
Articles Citing pCMV-Neo-Bam p53 R273H
Articles |
---|
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Sauer L, Gitenay D, Vo C, Baron VT. Oncogene. 2010 May 6;29(18):2628-37. doi: 10.1038/onc.2010.24. Epub 2010 Mar 1. PubMed |
Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. Saleh AD, Savage JE, Cao L, Soule BP, Ly D, DeGraff W, Harris CC, Mitchell JB, Simone NL. PLoS One. 2011;6(10):e24429. doi: 10.1371/journal.pone.0024429. Epub 2011 Oct 11. PubMed |
p53 and microRNA-34 are suppressors of canonical Wnt signaling. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, Kang SE, Cha SY, Ryu JK, Na JM, Park C, Kim K, Lee S, Gumbiner BM, Yook JI, Weiss SJ. Sci Signal. 2011 Nov 1;4(197):ra71. doi: 10.1126/scisignal.2001744. PubMed |
Expression of galectin-7 is induced in breast cancer cells by mutant p53. Campion CG, Labrie M, Lavoie G, St-Pierre Y. PLoS One. 2013 Aug 14;8(8):e72468. doi: 10.1371/journal.pone.0072468. eCollection 2013. PubMed |
Mutation or loss of p53 differentially modifies TGFbeta action in ovarian cancer. O hAinmhire E, Quartuccio SM, Cheng W, Ahmed RA, King SM, Burdette JE. PLoS One. 2014 Feb 20;9(2):e89553. doi: 10.1371/journal.pone.0089553. eCollection 2014. PubMed |
Expression and functions of galectin-7 in ovarian cancer. Labrie M, Vladoiu MC, Grosset AA, Gaboury L, St-Pierre Y. Oncotarget. 2014 Sep 15;5(17):7705-21. PubMed |
Mutant p53 expression in fallopian tube epithelium drives cell migration. Quartuccio SM, Karthikeyan S, Eddie SL, Lantvit DD, O hAinmhire E, Modi DA, Wei JJ, Burdette JE. Int J Cancer. 2015 Oct 1;137(7):1528-38. doi: 10.1002/ijc.29528. Epub 2015 Apr 11. PubMed |
p53 regulates the mevalonate pathway in human glioblastoma multiforme. Laezza C, D'Alessandro A, Di Croce L, Picardi P, Ciaglia E, Pisanti S, Malfitano AM, Comegna M, Faraonio R, Gazzerro P, Bifulco M. Cell Death Dis. 2015 Oct 15;6:e1909. doi: 10.1038/cddis.2015.279. PubMed |
Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface. Karthikeyan S, Lantvit DD, Chae DH, Burdette JE. Oncotarget. 2016 Oct 25;7(43):69871-69882. doi: 10.18632/oncotarget.11499. PubMed |
ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation. Morton DJ, Patel D, Joshi J, Hunt A, Knowell AE, Chaudhary J. Oncotarget. 2017 Jan 10;8(2):2536-2549. doi: 10.18632/oncotarget.13701. PubMed |
Delta40p53 suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells. Ota A, Nakao H, Sawada Y, Karnan S, Wahiduzzaman M, Inoue T, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Nakade Y, Sato K, Itoh K, Konishi H, Hosokawa Y, Yoneda M. J Cell Sci. 2016 Dec 15. pii: jcs.190736. PubMed |
Development of a genetic sensor that eliminates p53 deficient cells. Mircetic J, Dietrich A, Paszkowski-Rogacz M, Krause M, Buchholz F. Nat Commun. 2017 Nov 13;8(1):1463. doi: 10.1038/s41467-017-01688-w. PubMed |
Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM. Cancer Cell. 2018 Aug 13;34(2):298-314.e7. doi: 10.1016/j.ccell.2018.07.004. PubMed |
p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Yang-Hartwich Y, Tedja R, Roberts CM, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G. Mol Cancer Res. 2019 Jan;17(1):153-164. doi: 10.1158/1541-7786.MCR-18-0238. Epub 2018 Aug 21. PubMed |
ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK. PLoS One. 2018 Sep 18;13(9):e0204159. doi: 10.1371/journal.pone.0204159. eCollection 2018. PubMed |
Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells. Saini H, Hakeem I, Mukherjee S, Chowdhury S, Chowdhury R. J Oncol. 2019 Jan 6;2019:6164807. doi: 10.1155/2019/6164807. eCollection 2019. PubMed |
Mutant p53 amplifies a dynamin-1/APPL1 endosome feedback loop that regulates recycling and migration. Lakoduk AM, Roudot P, Mettlen M, Grossman HM, Schmid SL, Chen PH. J Cell Biol. 2019 Jun 3;218(6):1928-1942. doi: 10.1083/jcb.201810183. Epub 2019 May 1. PubMed |
The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, Liao H, Xu L, Wang D, Guo X. FEBS Open Bio. 2020 Apr;10(4):535-545. doi: 10.1002/2211-5463.12806. Epub 2020 Mar 6. PubMed |
Interaction of promyelocytic leukemia/p53 affects signal transducer and activator of transcription-3 activity in response to oncostatin M. Lim J, Choi JH, Park EM, Choi YH. Korean J Physiol Pharmacol. 2020 May 1;24(3):203-212. doi: 10.4196/kjpp.2020.24.3.203. PubMed |
Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells. Saini H, Sharma H, Mukherjee S, Chowdhury S, Chowdhury R. Cancer Cell Int. 2021 Jan 14;21(1):52. doi: 10.1186/s12935-020-01720-y. PubMed |
Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU via TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma. Gao X, Zheng X, Zhang Y, Dong L, Sun L, Zhao N, Ding C, Ma Z, Wang Y. Front Cell Dev Biol. 2022 Jan 5;9:788331. doi: 10.3389/fcell.2021.788331. eCollection 2021. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.